DMAC
$7.16
Post-MarketAs of Mar 17, 8:00 PM UTC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Recent News
DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings
Over the last year, a good number of insiders have significantly increased their holdings in DiaMedica Therapeutics...
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double
What makes analysts so bullish about these three names from the sector?
Microsoft initiated, Home Depot downgraded: Wall Street's top analyst calls
Microsoft initiated, Home Depot downgraded: Wall Street's top analyst calls